List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5756308/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	A Randomized Phase II Study of Nivolumab Monotherapy or Nivolumab Combined with Ipilimumab in Patients with Advanced Gastrointestinal Stromal Tumors. Clinical Cancer Research, 2022, 28, 84-94.	3.2	22
2	External Beam Radiation Therapy for Primary Liver Cancers: An ASTRO Clinical Practice Guideline. Practical Radiation Oncology, 2022, 12, 28-51.	1.1	92
3	The GIST of Advances in Treatment of Advanced Gastrointestinal Stromal Tumor. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2022, 42, 885-899.	1.8	21
4	Molecular and Immunologic Techniques in a Genetically Engineered Mouse Model of Gastrointestinal Stromal Tumor. Journal of Visualized Experiments, 2022, , .	0.2	1
5	Fourteen years of pancreatic surgery for malignancy among ACS-NSQIP centers: Trends in major morbidity and mortality. Surgery, 2022, 172, 708-714.	1.0	4
6	Opioid Use Disorder is Associated With Complications and Increased Length of Stay After Major Abdominal Surgery. Annals of Surgery, 2021, 274, 992-1000.	2.1	7
7	Prognostic Factors After Neoadjuvant Imatinib for Newly Diagnosed Primary Gastrointestinal Stromal Tumor. Journal of Gastrointestinal Surgery, 2021, 25, 1828-1836.	0.9	10
8	Impact of Primary Tumor Laterality on Adjuvant Hepatic Artery Infusion Pump Chemotherapy in Resected Colon Cancer Liver Metastases: Analysis of 487 Patients. Annals of Surgical Oncology, 2021, 28, 3685-3694.	0.7	3
9	Do microscopic surgical margins matter for primary gastric gastrointestinal stromal tumor?. Surgery, 2021, 169, 419-425.	1.0	4
10	Outcome of 1000 Patients With Gastrointestinal Stromal Tumor (GIST) Treated by Surgery in the Pre- and Post-imatinib Eras. Annals of Surgery, 2021, 273, 128-138.	2.1	62
11	Cancer-associated fibroblast secretion of PDGFC promotes gastrointestinal stromal tumor growth and metastasis. Oncogene, 2021, 40, 1957-1973.	2.6	22
12	Long-term Outcomes After Surgical Resection of Pancreatic Metastases from Renal Clear-Cell Carcinoma. Annals of Surgical Oncology, 2021, 28, 3100-3108.	0.7	18
13	Proposal of a New Comprehensive Notation for Hepatectomy. Annals of Surgery, 2021, 274, 1-3.	2.1	83
14	Oncogenic KIT Modulates Type I IFN–Mediated Antitumor Immunity in GIST. Cancer Immunology Research, 2021, 9, 542-553.	1.6	12
15	The Left Hepatic Bile Duct Is Not Longer?!. Annals of Surgery, 2021, 274, 35-36.	2.1	0
16	Surgical resection of gastric gastrointestinal stromal tumors (GIST) in octogenarians. American Journal of Surgery, 2021, , .	0.9	0
17	Gastric Neuroendocrine Tumors: Reappraisal of Type in Predicting Outcome. Annals of Surgical Oncology, 2021, 28, 8838-8846.	0.7	14
18	ASO Visual Abstract: Gastric Neuroendocrine Tumors: Reappraisal of Type in Predicting Outcome. Annals of Surgical Oncology, 2021, 28, 533-533.	0.7	0

#	Article	IF	CITATIONS
19	Genetic Determinants of Outcome in Intrahepatic Cholangiocarcinoma. Hepatology, 2021, 74, 1429-1444.	3.6	73
20	Impact of COVIDâ€19 Restrictions on Demographics and Outcomes of Patients Undergoing Medically Necessary Nonâ€Emergent Surgeries During the Pandemic. World Journal of Surgery, 2021, 45, 946-954.	0.8	6
21	Surgical Management of Sarcoma Metastatic to Liver. Surgical Oncology Clinics of North America, 2021, 30, 57-67.	0.6	5
22	The Cost of Quarantine. Annals of Surgery, 2021, 273, 844-849.	2.1	26
23	Identification of Wee1 as a target in combination with avapritinib for gastrointestinal stromal tumor treatment. JCI Insight, 2021, 6, .	2.3	5
24	What is the patient experience of surgical care during the coronavirus disease 2019 (COVID-19) pandemic? A mixed-methods study at a single institution. Surgery, 2021, 170, 550-557.	1.0	4
25	Defining the Safety Profile for Performing Pancreatoduodenectomy in the Setting of Hyperbilirubinemia. Annals of Surgical Oncology, 2020, 27, 1595-1605.	0.7	4
26	Assessment of Hepatic Arterial Infusion of Floxuridine in Combination With Systemic Gemcitabine and Oxaliplatin in Patients With Unresectable Intrahepatic Cholangiocarcinoma. JAMA Oncology, 2020, 6, 60.	3.4	112
27	Adjuvant Hepatic Artery Infusion Chemotherapy is Associated With Improved Survival Regardless of KRAS Mutation Status in Patients With Resected Colorectal Liver Metastases. Annals of Surgery, 2020, 272, 352-356.	2.1	21
28	Lending a hand for laparoscopic distal pancreatectomy: the optimal approach?. Hpb, 2020, 22, 690-701.	0.1	2
29	Choices of Therapeutic Strategies for Colorectal Liver Metastases Among Expert Liver Surgeons. Annals of Surgery, 2020, 272, 715-722.	2.1	53
30	A contemporary analysis of palliative procedures in aborted pancreatoduodenectomy: Morbidity, mortality, and impact on future therapy. Surgery, 2020, 168, 1026-1031.	1.0	8
31	Defining postoperative weight change after pancreatectomy: Factors associated with distinct and dynamic weight trajectories. Surgery, 2020, 168, 1041-1047.	1.0	4
32	The V654A second-site KIT mutation increases tumor oncogenesis and STAT activation in a mouse model of gastrointestinal stromal tumor. Oncogene, 2020, 39, 7153-7165.	2.6	8
33	Benchmarking Accomplishments of Leaders in American Surgery and Justification for Enhancing Diversity and Inclusion. Annals of Surgery, 2020, 272, 897-903.	2.1	30
34	Imatinib Activates Gamma Delta T (ydT) Cells in Gastrointestinal Stromal Tumor (GIST). Journal of the American College of Surgeons, 2020, 231, S268-S269.	0.2	1
35	Postoperative Outcomes and Practice Patterns in Extremity Sarcoma Management by Surgeon Specialty over Time: A National Cohort Study. Journal of the American College of Surgeons, 2020, 231, S277-S278.	0.2	0
36	Single-Cell Sequencing of the Immune Infiltrate of Gastrointestinal Stromal Tumor (GIST). Journal of the American College of Surgeons, 2020, 231, S280.	0.2	0

#	Article	IF	CITATIONS
37	COVID-19 Guideline Modifications as CMS Announces "Opening Up America Again†Comments from the Society of Surgical Oncology. Annals of Surgical Oncology, 2020, 27, 2111-2113.	0.7	6
38	Can We Coach Resilience? An Evaluation of Professional Resilience Coaching as a Well-Being Initiative for Surgical Interns. Journal of Surgical Education, 2020, 77, 1481-1489.	1.2	20
39	ILC2s amplify PD-1 blockade by activating tissue-specific cancer immunity. Nature, 2020, 579, 130-135.	13.7	229
40	Extended Experience with a Dynamic, Data-Driven Selective Drain Management Protocol in Pancreaticoduodenectomy: Progressive Risk Stratification for Better Practice. Journal of the American College of Surgeons, 2020, 230, 809-818e1.	0.2	21
41	Invasive central venous monitoring during hepatic resection: unnecessary for most patients. Hpb, 2020, 22, 1732-1737.	0.1	2
42	Quantitative imaging features of pretreatment CT predict volumetric response to chemotherapy in patients with colorectal liver metastases. European Radiology, 2019, 29, 458-467.	2.3	10
43	Hypophosphatemia as a Predictor of Organâ€5pecific Complications Following Gastrointestinal Surgery: Analysis of 8034ÂPatients. World Journal of Surgery, 2019, 43, 385-394.	0.8	7
44	Preoperative risk prediction for intraductal papillary mucinous neoplasms by quantitative CT image analysis. Hpb, 2019, 21, 212-218.	0.1	36
45	A phase Ib study of BGJ398, a pan-FGFR kinase inhibitor in combination with imatinib in patients with advanced gastrointestinal stromal tumor. Investigational New Drugs, 2019, 37, 282-290.	1.2	32
46	A rectal cancer organoid platform to study individual responses to chemoradiation. Nature Medicine, 2019, 25, 1607-1614.	15.2	320
47	Utility of Image Guidance in the Localization of Disappearing Colorectal Liver Metastases. Journal of Gastrointestinal Surgery, 2019, 23, 760-767.	0.9	9
48	Peripheral Circulating Tumor DNA Detection Predicts Poor Outcomes After Liver Resection for Metastatic Colorectal Cancer. Annals of Surgical Oncology, 2019, 26, 1824-1832.	0.7	31
49	Trends in practice patterns and outcomes: A decade of sarcoma care in the United States. Surgical Oncology, 2019, 29, 168-177.	0.8	6
50	Oncogenic kinase inhibition limits Batf3-dependent dendritic cell development and antitumor immunity. Journal of Experimental Medicine, 2019, 216, 1359-1376.	4.2	21
51	Csf1r or Mer inhibition delays liver regeneration via suppression of Kupffer cells. PLoS ONE, 2019, 14, e0216275.	1.1	11
52	Tailored management of primary gastrointestinal stromal tumors. Cancer, 2019, 125, 2164-2171.	2.0	20
53	Leading From the Front. Annals of Surgery, 2019, 269, 1012-1015.	2.1	62
54	Association of Overlapping, Nonconcurrent, Surgery With Patient Outcomes at a Large Academic Medical Center. Annals of Surgery, 2019, 270, 620-629.	2.1	18

#	Article	IF	CITATIONS
55	Regional differences in gallbladder cancer pathogenesis: Insights from a multiâ€institutional comparison of tumor mutations. Cancer, 2019, 125, 575-585.	2.0	34
56	Tumor mutational load predicts survival after immunotherapy across multiple cancer types. Nature Genetics, 2019, 51, 202-206.	9.4	2,702
57	Endoscopic versus percutaneous drainage of post-operative peripancreatic fluid collections following pancreatic resection. Hpb, 2019, 21, 434-443.	0.1	14
58	Differential immune profiles distinguish the mutational subtypes of gastrointestinal stromal tumor. Journal of Clinical Investigation, 2019, 129, 1863-1877.	3.9	56
59	Immune Response and Immunotherapy in GIST. , 2019, , 17-31.		Ο
60	Macrophages and CD8+ T Cells Mediate the Antitumor Efficacy of Combined CD40 Ligation and Imatinib Therapy in Gastrointestinal Stromal Tumors. Cancer Immunology Research, 2018, 6, 434-447.	1.6	49
61	Preoperative Risk Score to Predict Occult Metastatic or Locally Advanced Disease in Patients with Resectable Perihilar Cholangiocarcinoma on Imaging. Journal of the American College of Surgeons, 2018, 227, 238-246e2.	0.2	11
62	Quantitative Imaging Features and Postoperative Hepatic Insufficiency: A Multi-Institutional Expanded Cohort. Journal of the American College of Surgeons, 2018, 226, 835-843.	0.2	7
63	Extracellular matrix proteins and carcinoembryonic antigen-related cell adhesion molecules characterize pancreatic duct fluid exosomes in patients with pancreaticÂcancer. Hpb, 2018, 20, 597-604.	0.1	52
64	Actual 10-year survival after hepatic resection of colorectal liver metastases: what factors preclude cure?. Surgery, 2018, 163, 1238-1244.	1.0	147
65	Survival Prediction in Pancreatic Ductal Adenocarcinoma by Quantitative Computed Tomography Image Analysis. Annals of Surgical Oncology, 2018, 25, 1034-1042.	0.7	92
66	Mitochondrial Inhibition Augments the Efficacy of Imatinib by Resetting the Metabolic Phenotype of Gastrointestinal Stromal Tumor. Clinical Cancer Research, 2018, 24, 972-984.	3.2	42
67	Progression Patterns in the Remnant Pancreas after Resection of Non-Invasive or Micro-Invasive Intraductal Papillary Mucinous Neoplasms (IPMN). Annals of Surgical Oncology, 2018, 25, 1752-1759.	0.7	31
68	Development and Validation of a Multi-institutional Preoperative Nomogram for Predicting Grade of Dysplasia in Intraductal Papillary Mucinous Neoplasms (IPMNs) of the Pancreas. Annals of Surgery, 2018, 267, 157-163.	2.1	105
69	Cytoreductive Surgery for Metastatic Gastrointestinal Stromal Tumors Treated With Tyrosine Kinase Inhibitors. Annals of Surgery, 2018, 268, 296-302.	2.1	58
70	Incidence of Occult Intrahepatic Metastasis in Hepatocellular Carcinoma Treated With Transplantation Corresponds to Early Recurrence Rates After Partial Hepatectomy. Annals of Surgery, 2018, 267, 922-928.	2.1	34
71	Multi-institutional Validation Study of Pancreatic Cyst Fluid Protein Analysis for Prediction of High-risk Intraductal Papillary Mucinous Neoplasms of the Pancreas. Annals of Surgery, 2018, 268, 340-347.	2.1	39
72	The clinical utility of immunoglobulin G4 in the evaluation of autoimmune pancreatitis and pancreatic adenocarcinoma. Hpb, 2018, 20, 182-187.	0.1	17

#	Article	lF	CITATIONS
73	3D image guidance assisted identification of colorectal cancer liver metastases not seen on intraoperative ultrasound: results from a prospective trial. Hpb, 2018, 20, 260-267.	0.1	11
74	Prospective phase II trial of combination hepatic artery infusion and systemic chemotherapy for unresectable colorectal liver metastases: Long term results and curative potential. Journal of Surgical Oncology, 2018, 117, 634-643.	0.8	67
75	The Impact of Primary Tumor Location on Long-Term Survival in Patients Undergoing Hepatic Resection for Metastatic Colon Cancer. Annals of Surgical Oncology, 2018, 25, 431-438.	0.7	76
76	Can We Predict Incisional Hernia? Development of a Prediction Instrument Using the Health Care Cost and Utilization Project. Journal of the American College of Surgeons, 2018, 227, S95-S96.	0.2	0
77	Efficacy and Tolerability of 5-Year Adjuvant Imatinib Treatment for Patients With Resected Intermediate- or High-Risk Primary Gastrointestinal Stromal Tumor. JAMA Oncology, 2018, 4, e184060.	3.4	112
78	Characterization of hepatocellular adenoma and carcinoma using microRNA profiling and targeted gene sequencing. PLoS ONE, 2018, 13, e0200776.	1.1	30
79	A preoperative prognostic model to predict surgical success in patients with perihilar cholangiocarcinoma. Journal of Surgical Oncology, 2018, 118, 469-476.	0.8	15
80	Principles of Kinase Inhibitor Therapy for Solid Tumors. Annals of Surgery, 2017, 265, 311-319.	2.1	10
81	Percutaneous Peritoneal Lavage for the Rapid Staging of Gastric and Pancreatic Cancer. Annals of Surgical Oncology, 2017, 24, 1174-1179.	0.7	13
82	Operative morbidity and survival following hepatectomy for colorectal liver metastasis in octogenarians: a contemporary case matched series. Hpb, 2017, 19, 162-169.	0.1	21
83	Systemic Chemotherapy Combined with Resection for Locally Advanced Gallbladder Carcinoma: Surgical and Survival Outcomes. Journal of the American College of Surgeons, 2017, 224, 906-916.	0.2	56
84	Tumor-Associated Macrophage Infiltration in Colorectal Cancer Liver Metastases is Associated With Better Outcome. Annals of Surgical Oncology, 2017, 24, 1835-1842.	0.7	61
85	Recurrence patterns following irreversible electroporation for hepatic malignancies. Journal of Surgical Oncology, 2017, 115, 704-710.	0.8	31
86	Predicting Residual Disease in Incidental Gallbladder Cancer: Risk Stratification for Modified Treatment Strategies. Journal of Gastrointestinal Surgery, 2017, 21, 1254-1261.	0.9	24
87	Wnt/β-catenin Signaling Contributes to Tumor Malignancy and Is Targetable in Gastrointestinal Stromal Tumor. Molecular Cancer Therapeutics, 2017, 16, 1954-1966.	1.9	41
88	Natural History of Patients Followed Radiographically with Mucinous Cysts of the Pancreas. Journal of Gastrointestinal Surgery, 2017, 21, 1599-1605.	0.9	7
89	The Cost of Postoperative Pancreatic Fistula Versus the Cost of Pasireotide. Annals of Surgery, 2017, 265, 11-16.	2.1	53
90	Computed Tomography Image Texture: A Noninvasive Prognostic Marker of Hepatic Recurrence After Hepatectomy for Metastatic Colorectal Cancer. Annals of Surgical Oncology, 2017, 24, 2482-2490.	0.7	45

#	Article	IF	CITATIONS
91	Evolving application of minimally invasive cancer operations at a tertiary cancer center. Journal of Surgical Oncology, 2017, 115, 365-370.	0.8	7
92	Combined KIT and CTLA-4 Blockade in Patients with Refractory GIST and Other Advanced Sarcomas: A Phase Ib Study of Dasatinib plus Ipilimumab. Clinical Cancer Research, 2017, 23, 2972-2980.	3.2	106
93	Actual 10-Year Survivors After Resection of Hepatocellular Carcinoma. Annals of Surgical Oncology, 2017, 24, 1358-1366.	0.7	86
94	Preoperative Prediction of Microvascular Invasion in Hepatocellular Carcinoma Using Quantitative Image Analysis. Journal of the American College of Surgeons, 2017, 225, 778-788e1.	0.2	66
95	Rectal Gastrointestinal Stromal Tumor (GIST) in the Era of Imatinib: Organ Preservation and Improved Oncologic Outcome. Annals of Surgical Oncology, 2017, 24, 3972-3980.	0.7	59
96	Utility of Serum Inflammatory Markers for Predicting Microvascular Invasion and Survival for Patients with Hepatocellular Carcinoma. Annals of Surgical Oncology, 2017, 24, 3706-3714.	0.7	62
97	Direct engagement of the PI3K pathway by mutant KIT dominates oncogenic signaling in gastrointestinal stromal tumor. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, E8448-E8457.	3.3	34
98	Comparative "nocebo effects―in older patients enrolled in cancer therapeutic trials: Observations from a 446â€patient cohort. Cancer, 2017, 123, 4193-4198.	2.0	6
99	Identification of unique neoantigen qualities in long-term survivors of pancreatic cancer. Nature, 2017, 551, 512-516.	13.7	854
100	Postoperative Liver Failure Risk Score: Identifying Patients with Resectable Perihilar Cholangiocarcinoma Who Can Benefit from Portal Vein Embolization. Journal of the American College of Surgeons, 2017, 225, 387-394.	0.2	87
101	Hypophosphatemia after Hepatectomy or Pancreatectomy: Role of the Nicotinamide Phosphoribosyltransferase. Journal of the American College of Surgeons, 2017, 225, 488-497e2.	0.2	17
102	Prediction of Hepatocellular Carcinoma Recurrence Beyond Milan Criteria After Resection. Annals of Surgery, 2017, 266, 693-701.	2.1	86
103	Should Patients With Cystic Lesions of the Pancreas Undergo Long-term Radiographic Surveillance?. Annals of Surgery, 2017, 266, 536-544.	2.1	66
104	PD-1/PD-L1 Blockade Enhances T-cell Activity and Antitumor Efficacy of Imatinib in Gastrointestinal Stromal Tumors. Clinical Cancer Research, 2017, 23, 454-465.	3.2	126
105	Mutation location on the RAS oncogene affects pathologic features and survival after resection of colorectal liver metastases. Cancer, 2017, 123, 568-575.	2.0	39
106	Colorectal Cancer Liver Metastases and Concurrent Extrahepatic Disease Treated With Resection. Annals of Surgery, 2017, 265, 158-165.	2.1	115
107	Surgical Strategy and Outcomes in Duodenal Gastrointestinal Stromal Tumor. Annals of Surgical Oncology, 2017, 24, 202-210.	0.7	49
108	Perioperative Hepatic Arterial Infusion Pump Chemotherapy Is Associated With Longer Survival After Resection of Colorectal Liver Metastases: A Propensity Score Analysis. Journal of Clinical Oncology, 2017, 35, 1938-1944.	0.8	112

#	Article	IF	CITATIONS
109	Reply to A. Braillon, M. Boulin et al, and JH. Zhong et al. Journal of Clinical Oncology, 2017, 35, 258-259.	0.8	1
110	Title is missing!. , 2017, , .		8
111	Extended treatment with adjuvant imatinib (IM) for patients (pts) with high-risk primary gastrointestinal stromal tumor (GIST): The PERSIST-5 study Journal of Clinical Oncology, 2017, 35, 11009-11009.	0.8	8
112	The clinical impact of performing routine next generation sequencing (NGS) in gastrointestinal stromal tumors (GIST) Journal of Clinical Oncology, 2017, 35, 11010-11010.	0.8	3
113	Genome and transcriptome profiling of fibrolamellar hepatocellular carcinoma demonstrates p53 and IGF2BP1 dysregulation. PLoS ONE, 2017, 12, e0176562.	1.1	24
114	ETV4 collaborates with Wnt/ $\hat{l}^2$ -catenin signaling to alter cell cycle activity and promote tumor aggressiveness in gastrointestinal stromal tumor. Oncotarget, 2017, 8, 114195-114209.	0.8	25
115	Comparative nocebo effects in older patients enrolled in cancer therapeutic trials: Observations from a 446-patient cohort—NCCTG 97-24-51 and ACOSOG Z9001 (Alliance A151602) Journal of Clinical Oncology, 2017, 35, e21545-e21545.	0.8	0
116	Mutational profiling of resected intrahepatic cholangiocarcinoma Journal of Clinical Oncology, 2017, 35, e15675-e15675.	0.8	1
117	Extraordinary survivorship after colorectal liver metastasis resection to identify a distinct molecular profile associated with survival in an independent cohort of 965 patients Journal of Clinical Oncology, 2017, 35, 3581-3581.	0.8	Ο
118	Poor prognosis in patients with resectable KRAS-MUT colorectal liver metastases is improved by adjuvant hepatic arterial infusion chemotherapy Journal of Clinical Oncology, 2017, 35, e15161-e15161.	0.8	0
119	A phase Ib study of BGJ398 in combination with imatinib in patients with advanced gastrointestinal stromal tumor (GIST) Journal of Clinical Oncology, 2017, 35, 11039-11039.	0.8	Ο
120	Immunotherapy for Soft Tissue Sarcoma: Tomorrow Is Only a Day Away. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2016, 35, 281-290.	1.8	11
121	Unresectable intrahepatic cholangiocarcinoma: Systemic plus hepatic arterial infusion chemotherapy is associated with longer survival in comparison with systemic chemotherapy alone. Cancer, 2016, 122, 758-765.	2.0	138
122	Postoperative complications and overall survival after pancreaticoduodenectomy for pancreatic ductal adenocarcinoma. Journal of Surgical Oncology, 2016, 113, 188-193.	0.8	115
123	Recurrence Patterns after Irreversible Electroporation for Hepatic Metastases. Journal of the American College of Surgeons, 2016, 223, e144-e145.	0.2	Ο
124	Colorectal Cancer Liver Metastases: Biopsy of the Ablation Zone and Margins Can Be Used to Predict Oncologic Outcome. Radiology, 2016, 280, 949-959.	3.6	108
125	Duration of Adjuvant Therapy for Patients With Gastrointestinal Stromal Tumors. JAMA Oncology, 2016, 2, 721.	3.4	5
126	Health-Related Quality of Life After Pancreatectomy: Results From a Randomized Controlled Trial. Annals of Surgical Oncology, 2016, 23, 2137-2145.	0.7	41

#	Article	IF	CITATIONS
127	Robotic Liver Resection: A Caseâ€Matched Comparison. World Journal of Surgery, 2016, 40, 1422-1428.	0.8	86
128	Postoperative Mortality after Liver Resection for Perihilar Cholangiocarcinoma: Development of a Risk Score and Importance of Biliary Drainage of the Future Liver Remnant. Journal of the American College of Surgeons, 2016, 223, 321-331e1.	0.2	161
129	Long-term oncologic outcomes for simultaneous resection of synchronous metastatic liver and primary colorectal cancer. Surgery, 2016, 160, 67-73.	1.0	75
130	Time-to-Surgery and Survival Outcomes in Resectable Colorectal Liver Metastases: A Multi-Institutional Evaluation. Journal of the American College of Surgeons, 2016, 222, 766-779.	0.2	33
131	Outcomes of the Memorial Sloan Kettering Cancer Center International General Surgical Oncology Fellowship. Journal of the American College of Surgeons, 2016, 222, 961-966.	0.2	17
132	Recurrence Patterns and Disease-Free Survival after Resection of Intrahepatic Cholangiocarcinoma: Preoperative and Postoperative Prognostic Models. Journal of the American College of Surgeons, 2016, 223, 493-505e2.	0.2	101
133	A Multi-Institutional Validation Study of Pancreatic Cyst Fluid Protein Analysis for Prediction of High-Grade Dysplasia in Intraductal Papillary Mucinous Neoplasms. Journal of the American College of Surgeons, 2016, 223, S138.	0.2	2
134	Percutaneous Peritoneal Lavage for the Rapid Staging of Gastric and Pancreatic Cancer. Journal of the American College of Surgeons, 2016, 223, e185-e186.	0.2	0
135	Chronic Imatinib (>3 Years) Therapy after Complete Resection of Primary, High-Risk Gastrointestinal Stromal Tumor (GIST) Is Associated with Low Recurrence. Journal of the American College of Surgeons, 2016, 223, e44.	0.2	1
136	Prospective Randomized Controlled Trial of Liberal Vs Restricted Perioperative Fluid Management in Patients Undergoing Pancreatectomy. Annals of Surgery, 2016, 264, 591-598.	2.1	42
137	Updated longâ€ŧerm survival for patients with metastatic colorectal cancer treated with liver resection followed by hepatic arterial infusion and systemic chemotherapy. Journal of Surgical Oncology, 2016, 113, 477-484.	0.8	67
138	Hepatic Resection or Ablation for Isolated Breast Cancer Liver Metastasis. Annals of Surgery, 2016, 264, 147-154.	2.1	81
139	Symptomatic Perihepatic Fluid Collections After Hepatic Resection in the Modern Era. Journal of Gastrointestinal Surgery, 2016, 20, 748-756.	0.9	6
140	A Pilot Study Evaluating Serum MMP7 as a Preoperative Prognostic Marker for Pancreatic Ductal Adenocarcinoma Patients. Journal of Gastrointestinal Surgery, 2016, 20, 899-904.	0.9	20
141	Observation versus Resection for Small Asymptomatic Pancreatic Neuroendocrine Tumors: A Matched Case–Control Study. Annals of Surgical Oncology, 2016, 23, 1361-1370.	0.7	148
142	A Validated Prognostic Multigene Expression Assay for Overall Survival in Resected Colorectal Cancer Liver Metastases. Clinical Cancer Research, 2016, 22, 2575-2582.	3.2	40
143	The Role of Biliary Carcinoembryonic Antigen-Related Cellular Adhesion Molecule 6 (CEACAM6) as a Biomarker in Cholangiocarcinoma. PLoS ONE, 2016, 11, e0150195.	1.1	15
144	Circulating Plasma Levels of MicroRNA-21 and MicroRNA-221 Are Potential Diagnostic Markers for Primary Intrahepatic Cholangiocarcinoma. PLoS ONE, 2016, 11, e0163699.	1.1	52

#	Article	IF	CITATIONS
145	Immunotherapy for Soft Tissue Sarcoma: Tomorrow Is Only a Day Away. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2016, 36, 281-290.	1.8	3
146	Prospective evaluation of 18Fâ€fluorodeoxyglucose positron emission tomography in patients receiving hepatic arterial and systemic chemotherapy for unresectable colorectal liver metastases. Hpb, 2015, 17, 644-650.	0.1	5
147	Phase II Trial of Hepatic Artery Infusional and Systemic Chemotherapy for Patients With Unresectable Hepatic Metastases From Colorectal Cancer. Annals of Surgery, 2015, 261, 353-360.	2.1	171
148	Resection Margin and Survival in 2368 Patients Undergoing Hepatic Resection for Metastatic Colorectal Cancer. Annals of Surgery, 2015, 262, 476-485.	2.1	156
149	Tumor-associated Neutrophils and Malignant Progression in Intraductal Papillary Mucinous Neoplasms. Annals of Surgery, 2015, 262, 1102-1107.	2.1	37
150	Early trends in serum phosphate and creatinine levels are associated with mortality following major hepatectomy. Hpb, 2015, 17, 1058-1065.	0.1	13
151	Cholangiocarcinoma: Correlation between Molecular Profiling and Imaging Phenotypes. PLoS ONE, 2015, 10, e0132953.	1.1	50
152	Renal function after low central venous pressureâ€assisted liver resection: assessment of 2116 cases. Hpb, 2015, 17, 258-264.	0.1	42
153	Genetic Evidence That Intratumoral T-cell Proliferation and Activation Are Associated with Recurrence and Survival in Patients with Resected Colorectal Liver Metastases. Cancer Immunology Research, 2015, 3, 380-388.	1.6	30
154	EBV-associated lymphoepithelioma-like carcinoma of the pancreas: Case report with targeted sequencing analysis. Pancreatology, 2015, 15, 302-304.	0.5	13
155	<i>CCR</i> 20th Anniversary Commentary: A Genetic Mechanism of Imatinib Resistance in Gastrointestinal Stromal Tumor—Where Are We a Decade Later?. Clinical Cancer Research, 2015, 21, 3363-3365.	3.2	17
156	Central hepatectomy versus extended hepatectomy for liver malignancy: a matched cohort comparison. Hpb, 2015, 17, 1025-1032.	0.1	21
157	Hospital readmissions after liver surgery for metastatic colorectal cancer. Surgery, 2015, 157, 231-238.	1.0	11
158	Recurrence After Partial Hepatectomy for Metastatic Colorectal Cancer: Potentially Curative Role of Salvage Repeat Resection. Annals of Surgical Oncology, 2015, 22, 2761-2771.	0.7	79
159	Texture Analysis of Preoperative CT Images for Prediction of Postoperative Hepatic Insufficiency: A Preliminary Study. Journal of the American College of Surgeons, 2015, 220, 339-346.	0.2	46
160	Chemotherapy-Induced Splenic Volume Increase Is Independently Associated with Major Complications after Hepatic Resection for Metastatic Colorectal Cancer. Journal of the American College of Surgeons, 2015, 220, 271-280.	0.2	30
161	Prognostic factors in fibrolamellar hepatocellular carcinoma in young people. Journal of Pediatric Surgery, 2015, 50, 153-156.	0.8	54
162	Additional Primary Malignancies in Patients with Gastrointestinal Stromal Tumor (GIST): A Clinicopathologic Study of 260 Patients with Molecular Analysis and Review of the Literature. Annals of Surgical Oncology, 2015, 22, 2633-2639.	0.7	46

#	Article	IF	CITATIONS
163	Positive Postoperative CEA is a Strong Predictor of Recurrence for Patients After Resection for Colorectal Liver Metastases. Annals of Surgical Oncology, 2015, 22, 3087-3093.	0.7	34
164	Development and Assessment of Memorial Sloan Kettering Cancer Center's Surgical Secondary Events Grading System. Annals of Surgical Oncology, 2015, 22, 1061-1067.	0.7	93
165	Locoregional Therapy for Hepatocellular Carcinoma with and without Extrahepatic Spread. Journal of Vascular and Interventional Radiology, 2015, 26, 1112-1121.	0.2	8
166	Hepatic Parenchymal Preservation Surgery: Decreasing Morbidity and Mortality Rates in 4,152 Resections for Malignancy. Journal of the American College of Surgeons, 2015, 220, 471-479.	0.2	138
167	Percutaneous Preoperative Biliary Drainage for Resectable Perihilar Cholangiocarcinoma: No Association with Survival and No Increase in Seeding Metastases. Annals of Surgical Oncology, 2015, 22, 1156-1163.	0.7	44
168	Outcomes after Resection of Intrahepatic Cholangiocarcinoma: External Validation and Comparison of Prognostic Models. Journal of the American College of Surgeons, 2015, 221, 452-461.	0.2	70
169	FOLFIRINOX Induction Therapy for Stage 3 Pancreatic Adenocarcinoma. Annals of Surgical Oncology, 2015, 22, 3512-3521.	0.7	135
170	Liver myeloid-derived suppressor cells expand in response to liver metastases in mice and inhibit the anti-tumor efficacy of anti-CEA CAR-T. Cancer Immunology, Immunotherapy, 2015, 64, 817-829.	2.0	184
171	Clinical Features and Outcome of Primary Pancreatic Lymphoma. Annals of Surgical Oncology, 2015, 22, 1176-1184.	0.7	36
172	Goal-Directed Fluid Therapy Using Stroke Volume Variation for Resuscitation after Low Central Venous Pressure-Assisted Liver Resection: A Randomized Clinical Trial. Journal of the American College of Surgeons, 2015, 221, 591-601.	0.2	62
173	Nomograms in oncology: more than meets the eye. Lancet Oncology, The, 2015, 16, e173-e180.	5.1	2,187
174	Recurrence Rate and Pattern of Perihilar Cholangiocarcinoma after Curative Intent Resection. Journal of the American College of Surgeons, 2015, 221, 1041-1049.	0.2	143
175	Intraductal Papillary Mucinous Neoplasms and the Risk of Diabetes Mellitus in Patients Undergoing Resection Versus Observation. Journal of Gastrointestinal Surgery, 2015, 19, 1974-1981.	0.9	27
176	Pharmacological Inhibition of KIT Activates MET Signaling in Gastrointestinal Stromal Tumors. Cancer Research, 2015, 75, 2061-2070.	0.4	46
177	Simultaneous resection for rectal cancer with synchronous liver metastasis is a safe procedure. American Journal of Surgery, 2015, 209, 935-942.	0.9	84
178	Distal Pancreatectomy: A Single Institution's Experience in Open, Laparoscopic, and Robotic Approaches. Journal of the American College of Surgeons, 2015, 220, 18-27.	0.2	177
179	Sarcoma response to targeted therapy dynamically polarizes tumor-associated macrophages. Oncolmmunology, 2014, 3, e28463.	2.1	5
180	Sustained Inhibition of Receptor Tyrosine Kinases and Macrophage Depletion by PLX3397 and Rapamycin as a Potential New Approach for the Treatment of MPNSTs. Clinical Cancer Research, 2014, 20, 3146-3158.	3.2	86

#	Article	IF	CITATIONS
181	Pasireotide for Postoperative Pancreatic Fistula. New England Journal of Medicine, 2014, 370, 2014-2022.	13.9	353
182	<i>KRAS</i> mutation influences recurrence patterns in patients undergoing hepatic resection of colorectal metastases. Cancer, 2014, 120, 3965-3971.	2.0	127
183	Impact of pre-operative positron emission tomography in gallbladder cancer. Hpb, 2014, 16, 1023-1030.	0.1	36
184	Timing of elective surgery as a perioperative outcome variable: analysis of pancreaticoduodenectomy. Hpb, 2014, 16, 250-262.	0.1	23
185	Adjuvant Imatinib for GIST: The Pie is Shrinking. Annals of Surgical Oncology, 2014, 21, 3365-3366.	0.7	1
186	Predicting recurrence patterns after resection of hepatocellular cancer. Hpb, 2014, 16, 943-953.	0.1	54
187	Readmission After Pancreatic Resection: Causes and Causality Pattern. Annals of Surgical Oncology, 2014, 21, 4342-4350.	0.7	46
188	Increased KIT Inhibition Enhances Therapeutic Efficacy in Gastrointestinal Stromal Tumor. Clinical Cancer Research, 2014, 20, 2350-2362.	3.2	44
189	Safe and Successful Yttrium-90 Resin Microsphere Radioembolization in a Heavily Pretreated Patient with Chemorefractory Colorectal Liver Metastases after Biliary Stent Placement above the Papilla. Case Reports in Hepatology, 2014, 2014, 1-4.	0.4	3
190	American Joint Committee on Cancer staging for resected perihilar cholangiocarcinoma: a comparison of the 6th and 7th editions. Hpb, 2014, 16, 1074-1082.	0.1	46
191	Pathologic Grade and Tumor Size are Associated with Recurrence-Free Survival in Patients with Duodenal Neuroendocrine Tumors. Journal of Gastrointestinal Surgery, 2014, 18, 457-463.	0.9	68
192	The GIST of Targeted Therapy for Malignant Melanoma. Annals of Surgical Oncology, 2014, 21, 2059-2067.	0.7	17
193	Minimally-Invasive vs Open Pancreaticoduodenectomy: Systematic Review and Meta-Analysis. Journal of the American College of Surgeons, 2014, 218, 129-139.	0.2	160
194	Treatment of Extensive Metastatic Colorectal Cancer to the Liver with Systemic and Hepatic Arterial Infusion Chemotherapy and Two-Stage Hepatic Resection: The Role of Salvage Therapy for Recurrent Disease. Annals of Surgical Oncology, 2014, 21, 815-821.	0.7	32
195	Prognostic Significance of the Highest Peripancreatic Lymph Node in Biliary Tract Adenocarcinoma. Annals of Surgical Oncology, 2014, 21, 979-985.	0.7	9
196	Floxuridine Hepatic Arterial Infusion Associated Biliary Toxicity Is Increased by Concurrent Administration of Systemic Bevacizumab. Annals of Surgical Oncology, 2014, 21, 479-486.	0.7	39
197	Pharmacologic Prophylaxis, Postoperative INR, and Risk of Venous Thromboembolism after Hepatectomy. Journal of Gastrointestinal Surgery, 2014, 18, 295-303.	0.9	24
198	Endoscopic Ultrasound-Guided Transmural Drainage of Postoperative Pancreatic Collections. Journal of the American College of Surgeons, 2014, 218, 33-40.	0.2	75

#	Article	IF	CITATIONS
199	Gastrointestinal Stromal Tumors. Advances in Surgery, 2014, 48, 165-183.	0.6	38
200	Risk factors for gastrointestinal stromal tumor recurrence in patients treated with adjuvant imatinib. Cancer, 2014, 120, 2325-2333.	2.0	65
201	FOLFIRINOX induction therapy for stage III pancreatic adenocarcinoma. Journal of the American College of Surgeons, 2014, 219, e176.	0.2	0
202	Choledochal cysts: a clinicopathologic study of 36 cases with emphasis on the morphologic and the immunohistochemical features of premalignant and malignant alterations. Human Pathology, 2014, 45, 2107-2114.	1.1	53
203	Regional Chemotherapy for Unresectable Intrahepatic Cholangiocarcinoma: A Potential Role for Dynamic Magnetic Resonance Imaging as an Imaging Biomarker and a Survival Update from Two Prospective Clinical Trials. Annals of Surgical Oncology, 2014, 21, 2675-2683.	0.7	38
204	A Retrospective Comparison of Microwave Ablation vs. Radiofrequency Ablation for Colorectal Cancer Hepatic Metastases. Annals of Surgical Oncology, 2014, 21, 4278-4283.	0.7	151
205	Uncinate Duct Dilation in Intraductal Papillary Mucinous Neoplasms of the Pancreas: A Radiographic Finding with Potentially Increased Malignant Potential. Journal of Gastrointestinal Surgery, 2014, 18, 911-916.	0.9	12
206	Remnant Growth Rate after Portal Vein Embolization Is a Good Early Predictor of Post-Hepatectomy Liver Failure. Journal of the American College of Surgeons, 2014, 219, 620-630.	0.2	84
207	PD-1/PD-L1 Blockade Enhances the Efficacy of Imatinib in Gastrointestinal Stromal Tumor (GIST). Journal of the American College of Surgeons, 2014, 219, S129.	0.2	3
208	Tumor MHC Class I Expression Improves the Prognostic Value of T-cell Density in Resected Colorectal Liver Metastases. Cancer Immunology Research, 2014, 2, 530-537.	1.6	43
209	Residual Disease Predicts Outcomes after Definitive Resection for Incidental Gallbladder Cancer. Journal of the American College of Surgeons, 2014, 219, 416-429.	0.2	65
210	Pathologic and Molecular Features Correlate With Long-Term Outcome After Adjuvant Therapy of Resected Primary GI Stromal Tumor: The ACOSOG Z9001 Trial. Journal of Clinical Oncology, 2014, 32, 1563-1570.	0.8	252
211	A Single-Arm, Nonrandomized Phase II Trial of Neoadjuvant Gemcitabine and Oxaliplatin in Patients With Resectable Pancreas Adenocarcinoma. Annals of Surgery, 2014, 260, 142-148.	2.1	121
212	Liberal Resection for (Presumed) Sendai Negative Branch-Duct Intraductal Papillary Mucinous Neoplasms— Also Not Harmless. Annals of Surgery, 2014, 259, e45.	2.1	15
213	Response rates to hepatic arterial infusion (HAI) pump therapy in patients with metastatic colorectal cancer liver metastases (mCRC LM) after progression on all standard chemotherapies Journal of Clinical Oncology, 2014, 32, 597-597.	0.8	1
214	Combined Ablation and Resection (CARe) as an Effective Parenchymal Sparing Treatment for Extensive Colorectal Liver Metastases. PLoS ONE, 2014, 9, e114404.	1.1	63
215	Comparison Between Perioperative and Postoperative Chemotherapy After Potentially Curative Hepatic Resection for Metastatic Colorectal Cancer. Annals of Surgical Oncology, 2013, 20, 4312-4321.	0.7	55
216	Conversion to Complete Resection and/or Ablation Using Hepatic Artery Infusional Chemotherapy in Patients with Unresectable Liver Metastases from Colorectal Cancer: A Decade of Experience at a Single Institution. Annals of Surgical Oncology, 2013, 20, 2901-2907.	0.7	49

#	Article	IF	CITATIONS
217	Angiogenesis inhibition augments the effect of imatinib in gastrointestinal stromal tumor. Journal of the American College of Surgeons, 2013, 217, S140.	0.2	2
218	Hepatic Pedicle Clamping During Hepatic Resection for Colorectal Liver Metastases: No Impact on Survival or Hepatic Recurrence. Annals of Surgical Oncology, 2013, 20, 285-294.	0.7	38
219	Regulatory T Cell Infiltration Predicts Outcome Following Resection of Colorectal Cancer Liver Metastases. Annals of Surgical Oncology, 2013, 20, 946-955.	0.7	141
220	Regional Differences in Gallbladder Cancer Pathogenesis: Insights from a Comparison of Cell Cycle-Regulatory, PI3K, and Pro-Angiogenic Protein Expression. Annals of Surgical Oncology, 2013, 20, 1470-1481.	0.7	10
221	Predicting Dysplasia and Invasive Carcinoma in Intraductal Papillary Mucinous Neoplasms of the Pancreas: Development of a Preoperative Nomogram. Annals of Surgical Oncology, 2013, 20, 4348-4355.	0.7	87
222	Pancreas and Liver Resection in Jehovah's Witness Patients: Feasible and Safe. Journal of the American College of Surgeons, 2013, 217, 1101-1107.	0.2	20
223	Vascular inflow control during hemiâ€hepatectomy: a comparison between intrahepatic pedicle ligation and extrahepatic vascular ligation. Hpb, 2013, 15, 449-456.	0.1	6
224	Selecting Patients for Acute Normovolemic Hemodilution during Hepatic Resection: A Prospective Randomized Evaluation of Nomogram-Based Allocation. Journal of the American College of Surgeons, 2013, 217, 210-220.	0.2	16
225	Preoperative Chemotherapy and the Risk of Hepatotoxicity and Morbidity after Liver Resection for Metastatic Colorectal Cancer: A Single Institution Experience. Journal of the American College of Surgeons, 2013, 216, 41-49.	0.2	77
226	Changes in the management of benign liver tumours: an analysis of 285 patients. Hpb, 2013, 15, 156-163.	0.1	33
227	Management of hepatocellular adenoma: comparison of resection, embolization and observation. Hpb, 2013, 15, 235-243.	0.1	46
228	Long-term Outcomes Following Tumor Ablation for Treatment of Bilateral Colorectal Liver Metastases. JAMA Surgery, 2013, 148, 597.	2.2	84
229	Risk of Occult Irresectable Disease at Liver Resection for Hepatic Colorectal Cancer Metastases: A Contemporary Analysis. Annals of Surgical Oncology, 2013, 20, 2029-2034.	0.7	9
230	Blood Neutrophil-to-Lymphocyte Ratio is Prognostic in Gastrointestinal Stromal Tumor. Annals of Surgical Oncology, 2013, 20, 593-599.	0.7	64
231	Incidentally Discovered Pancreatic Intraepithelial Neoplasia: What Is Its Clinical Significance?. Annals of Surgical Oncology, 2013, 20, 3643-3647.	0.7	35
232	Long-term Results of Adjuvant Imatinib Mesylate in Localized, High-Risk, Primary Gastrointestinal Stromal Tumor. Annals of Surgery, 2013, 258, 422-429.	2.1	150
233	Chemotherapy After Portal Vein Embolization to Protect Against Tumor Growth During Liver Hypertrophy Before Hepatectomy. JAMA Surgery, 2013, 148, 1103.	2.2	89
234	Does preâ€operative chemoradiation for initially unresectable or borderline resectable pancreatic adenocarcinoma increase postâ€operative morbidity? A caseâ€matched analysis. Hpb, 2013, 15, 574-580.	0.1	34

#	Article	IF	CITATIONS
235	Prognostic significance of early recurrence: a conditional survival analysis in patients with resected colorectal liver metastasis. Hpb, 2013, 15, 803-813.	0.1	44
236	Dysplasia at the surgical margin is associated with recurrence after resection of nonâ€invasive intraductal papillary mucinous neoplasms. Hpb, 2013, 15, 814-821.	0.1	52
237	Biliary Self-Expandable Metal Stents Do Not Adversely Affect Pancreaticoduodenectomy. American Journal of Gastroenterology, 2013, 108, 1168-1173.	0.2	77
238	KIT oncogene inhibition drives intratumoral macrophage M2 polarization. Journal of Experimental Medicine, 2013, 210, 2873-2886.	4.2	116
239	Failure Patterns in Resected Pancreas Adenocarcinoma. Annals of Surgery, 2013, 258, 331-335.	2.1	68
240	Operative Drainage Following Pancreatic Resection. Annals of Surgery, 2013, 258, 1051-1058.	2.1	138
241	Gastrointestinal Stromal Tumors, Somatic Mutations and Candidate Genetic Risk Variants. PLoS ONE, 2013, 8, e62119.	1.1	19
242	Association of KRAS mutation with worse recurrence-free survival and site of metastatic progression after resection of hepatic colorectal metastases Journal of Clinical Oncology, 2013, 31, 3609-3609.	0.8	1
243	Influence of KRAS mutation on recurrence patterns in patients undergoing hepatic resection of colorectal metastases Journal of Clinical Oncology, 2013, 31, 398-398.	0.8	1
244	Gene Expression Profiles Accurately Predict Outcome Following Liver Resection in Patients with Metastatic Colorectal Cancer. PLoS ONE, 2013, 8, e81680.	1.1	33
245	Survival after resection plus intra-operative radiofrequency ablation (IRFA) to treat colorectal liver metastases (CLM): Results of an international collaborative study Journal of Clinical Oncology, 2013, 31, 3558-3558.	0.8	2
246	Hepatic arterial infusion for unresectable intrahepatic cholangiocarcinoma: An update on survival from two prospective clinical trials Journal of Clinical Oncology, 2013, 31, 4116-4116.	0.8	0
247	Clinicopathologic characteristics and survival outcomes of patients with fibrolamellar carcinoma: data from the fibrolamellar carcinoma consortium. Gastrointestinal Cancer Research: GCR, 2013, 6, 3-9.	0.8	50
248	Opposing roles of RAGE and Myd88 signaling in extensive liver resection. FASEB Journal, 2012, 26, 882-893.	0.2	30
249	Hemorrhagic Pseudoaneurysm in a Patient Receiving Aflibercept for Metastatic Thyroid Cancer. Thyroid, 2012, 22, 552-555.	2.4	4
250	Resection Versus Transplantation for Early Hepatocellular Carcinoma. Annals of Surgery, 2012, 256, 892-893.	2.1	8
251	Contemporary Experience with Postpancreatectomy Hemorrhage: Results of 1,122 Patients Resected between 2006 and 2011. Journal of the American College of Surgeons, 2012, 215, 616-621.	0.2	90
252	Ablation of Perivascular Hepatic Malignant Tumors with Irreversible Electroporation. Journal of the American College of Surgeons, 2012, 215, 379-387.	0.2	240

#	Article	IF	CITATIONS
253	The Blumgart Preoperative Staging System for Hilar Cholangiocarcinoma: Analysis of Resectability and Outcomes in 380 Patients. Journal of the American College of Surgeons, 2012, 215, 343-355.	0.2	184
254	Resection of Adrenocortical Carcinoma Liver Metastasis: Is it Justified?. Annals of Surgical Oncology, 2012, 19, 2643-2651.	0.7	64
255	Ki-67 is a Prognostic Biomarker of Survival after Radiofrequency Ablation of Liver Malignancies. Annals of Surgical Oncology, 2012, 19, 4262-4269.	0.7	62
256	Operative procedures for unresectable pancreatic cancer: does operative bypass decrease requirements for postoperative procedures and in-hospital days?. Hpb, 2012, 14, 469-475.	0.1	23
257	Synchronous Resection of Primary and Liver Metastases for Neuroendocrine Tumors. Annals of Surgical Oncology, 2012, 19, 4270-4277.	0.7	60
258	Nilotinib protects the murine liver from ischemia/reperfusion injury. Journal of Hepatology, 2012, 57, 766-773.	1.8	46
259	Intraductal papillary neoplasm of the bile duct: A biliary equivalent to intraductal papillary mucinous neoplasm of the pancreas?. Hepatology, 2012, 56, 1352-1360.	3.6	229
260	Impact of Obesity and Body Fat Distribution on Survival After Pancreaticoduodenectomy for Pancreatic Adenocarcinoma. Annals of Surgical Oncology, 2012, 19, 2908-2916.	0.7	45
261	Pathologic Response to Preoperative Chemotherapy in Colorectal Liver Metastases: Fibrosis, not Necrosis, Predicts Outcome. Annals of Surgical Oncology, 2012, 19, 2797-2804.	0.7	53
262	The Management of Gastrointestinal Stromal Tumors: A Model for Targeted and Multidisciplinary Therapy of Malignancy. Annual Review of Medicine, 2012, 63, 247-258.	5.0	119
263	Personalized Therapy: Prognostic Factors in Gastrointestinal Stromal Tumor (GIST). Journal of Gastrointestinal Surgery, 2012, 16, 1645-1647.	0.9	12
264	A Novel Survival-Based Tissue Microarray of Pancreatic Cancer Validates MUC1 and Mesothelin as Biomarkers. PLoS ONE, 2012, 7, e40157.	1.1	99
265	Is Port Site Resection Necessary in the Surgical Management of Gallbladder Cancer?. Annals of Surgical Oncology, 2012, 19, 409-417.	0.7	118
266	Survival after Resection of Pancreatic Adenocarcinoma: Results from a Single Institution over Three Decades. Annals of Surgical Oncology, 2012, 19, 169-175.	0.7	307
267	Patterns of failure in patients with early onset (synchronous) resectable liver metastases from rectal cancer. Cancer, 2012, 118, 5414-5423.	2.0	33
268	Microscopically Positive Margins for Primary Gastrointestinal Stromal Tumors: Analysis of Risk Factors and Tumor Recurrence. Journal of the American College of Surgeons, 2012, 215, 53-59.	0.2	141
269	Biliary Sclerosis after Hepatic Arterial Infusion Pump Chemotherapy for Patients with Colorectal Cancer Liver Metastasis: Incidence, Clinical Features, and Risk Factors. Annals of Surgical Oncology, 2012, 19, 1609-1617.	0.7	73
270	CD133 and CD44 are universally overexpressed in GIST and do not represent cancer stem cell markers. Genes Chromosomes and Cancer, 2012, 51, 186-195.	1.5	17

#	Article	IF	CITATIONS
271	ls conversion to resection possible with hepatic arterial infusion (HAI)Âand systemic (SYS) even in previously treated patients (pts)Âwith unresectable colorectal liver metastases (UnCLM)?. Journal of Clinical Oncology, 2012, 30, 3577-3577.	0.8	1
272	Conversion to complete surgical treatment using hepatic artery infusional chemotherapy in patients with unresectable liver metastases from colorectal cancer Journal of Clinical Oncology, 2012, 30, 472-472.	0.8	0
273	Significance of CEACAM6 expression in biliary tract carcinoma Journal of Clinical Oncology, 2012, 30, 207-207.	0.8	0
274	Effect of perioperative complications on recurrence and survival after resection of hepatic colorectal metastases: Analysis of data from a randomized controlled trial Journal of Clinical Oncology, 2012, 30, 3620-3620.	0.8	1
275	Advances in the Surgical Management of Gastrointestinal Stromal Tumor. Advances in Surgery, 2011, 45, 197-209.	0.6	32
276	Imatinib potentiates antitumor T cell responses in gastrointestinal stromal tumor through the inhibition of Ido. Nature Medicine, 2011, 17, 1094-1100.	15.2	476
277	Invasive Carcinoma Arising in Intraductal Papillary Mucinous Neoplasms of the Pancreas. Annals of Surgery, 2011, 253, 968-974.	2.1	107
278	Comparative Analysis of Outcome in Patients With Hepatocellular Carcinoma Exceeding the Milan Criteria Treated With Liver Transplantation Versus Partial Hepatectomy. American Journal of Clinical Oncology: Cancer Clinical Trials, 2011, 34, 466-471.	0.6	16
279	Comparison of Adjuvant Systemic Chemotherapy With or Without Hepatic Arterial Infusional Chemotherapy After Hepatic Resection for Metastatic Colorectal Cancer. Annals of Surgery, 2011, 254, 851-856.	2.1	100
280	Accurate Staging for Gallbladder Cancer. Annals of Surgery, 2011, 254, 320-325.	2.1	186
281	Post-hepatectomy haemorrhage: a definition and grading by the International Study Group of Liver Surgery (ISGLS). Hpb, 2011, 13, 528-535.	0.1	312
282	The role of laparoscopic staging in patients with incidental gallbladder cancer. Hpb, 2011, 13, 463-472.	0.1	72
283	High-grade dysplasia of the cystic duct margin in the absence of malignancy after cholecystectomy. Hpb, 2011, 13, 865-868.	0.1	23
284	Resection of perihilar biliary schwannoma. Surgical Oncology, 2011, 20, e157-e159.	0.8	11
285	Gallbladder Cancer: Differences in Presentation, Surgical Treatment, and Survival in Patients Treated at Centers in Three Countries. Journal of the American College of Surgeons, 2011, 212, 50-61.	0.2	100
286	Cystic Lesions of the Pancreas: Changes in the Presentation and Management of 1,424 Patients at a Single Institution over a 15-Year Time Period. Journal of the American College of Surgeons, 2011, 212, 590-600.	0.2	210
287	Imatinib modulates tumor associated macrophages in gastrointestinal stromal tumor (GIST). Journal of the American College of Surgeons, 2011, 213, S142-S143.	0.2	0
288	Folate receptor- $\hat{I}$ ± expression in resectable hepatic colorectal cancer metastases: patterns and significance. Modern Pathology, 2011, 24, 1221-1228.	2.9	48

#	Article	IF	CITATIONS
289	Effect on Outcome of Recurrence Patterns After Hepatectomy for Colorectal Metastases. Annals of Surgical Oncology, 2011, 18, 1096-1103.	0.7	162
290	Laparoscopic Versus Open Gastric Resections for Primary Gastrointestinal Stromal Tumors (GISTs): A Size-Matched Comparison. Annals of Surgical Oncology, 2011, 18, 1599-1605.	0.7	160
291	Antiangiogenic Therapy for Primary Liver Cancer: Correlation of Changes in Dynamic Contrast-Enhanced Magnetic Resonance Imaging with Tissue Hypoxia Markers and Clinical Response. Annals of Surgical Oncology, 2011, 18, 2192-2199.	0.7	76
292	Solid Pseudopapillary Tumors of the Pancreas. Clinical Features, Surgical Outcomes, and Long-Term Survival in 45 Consecutive Patients from a Single Center. Journal of Gastrointestinal Surgery, 2011, 15, 350-357.	0.9	160
293	Use of Intraoperative Ablation as an Adjunct to Surgical Resection in the Treatment of Recurrent Colorectal Liver Metastases. Journal of Gastrointestinal Surgery, 2011, 15, 1168-1172.	0.9	11
294	Obstructive Jaundice Expands Intrahepatic Regulatory T Cells, Which Impair Liver T Lymphocyte Function but Modulate Liver Cholestasis and Fibrosis. Journal of Immunology, 2011, 187, 1150-1156.	0.4	79
295	Randomized Phase II Trial of Adjuvant Hepatic Arterial Infusion and Systemic Chemotherapy With or Without Bevacizumab in Patients With Resected Hepatic Metastases From Colorectal Cancer. Journal of Clinical Oncology, 2011, 29, 884-889.	0.8	106
296	Adequate Lymph Node Assessment for Extrahepatic Bile Duct Adenocarcinoma. Annals of Surgery, 2010, 251, 675-681.	2.1	129
297	Relationship Between Intraoperative Fluid Administration and Perioperative Outcome After Pancreaticoduodenectomy. Annals of Surgery, 2010, 252, 952-958.	2.1	104
298	NCCN Task Force Report: Update on the Management of Patients with Gastrointestinal Stromal Tumors. Journal of the National Comprehensive Cancer Network: JNCCN, 2010, 8, S-1-S-41.	2.3	1,004
299	Natural History of Patients with Subcentimeter Pulmonary Nodules Undergoing Hepatic Resection for Metastatic Colorectal Cancer. Journal of the American College of Surgeons, 2010, 210, 31-38.	0.2	58
300	Survival after Hepatic Resection for Metastatic Colorectal Cancer: Trends in Outcomes for 1,600 Patients during Two Decades at a Single Institution. Journal of the American College of Surgeons, 2010, 210, 744-752.	0.2	425
301	Electronic Synoptic Operative Reporting: Assessing the Reliability and Completeness of Synoptic Reports for Pancreatic Resection. Journal of the American College of Surgeons, 2010, 211, 308-315.	0.2	67
302	Laparoscopic Distal Pancreatectomy: Evolution of a Technique at a Single Institution. Journal of the American College of Surgeons, 2010, 211, 503-509.	0.2	168
303	Toll-like receptor 9 inhibition confers protection from liver ischemia-reperfusion injury. Hepatology, 2010, 51, 621-632.	3.6	176
304	T cell infiltrate and outcome following resection of intermediate-grade primary neuroendocrine tumours and liver metastases. Hpb, 2010, 12, 674-683.	0.1	75
305	Neutrophil IL-10 suppresses peritoneal inflammatory monocytes during polymicrobial sepsis. Journal of Leukocyte Biology, 2010, 89, 423-432.	1.5	68
306	Conventional DCs reduce liver ischemia/reperfusion injury in mice via IL-10 secretion. Journal of Clinical Investigation, 2010, 120, 559-569.	3.9	169

#	Article	IF	CITATIONS
307	Protocol for the Examination of Specimens From Patients With Gastrointestinal Stromal Tumor. Archives of Pathology and Laboratory Medicine, 2010, 134, 165-170.	1.2	57
308	Incidentally discovered, intra-abdominal metallic foreign object on preoperative imaging. American Surgeon, 2010, 76, E180-1.	0.4	0
309	The Lytic Potential of Human Liver NK Cells Is Restricted by Their Limited Expression of Inhibitory Killer Ig-Like Receptors. Journal of Immunology, 2009, 183, 1789-1796.	0.4	55
310	Mechanisms of Sunitinib Resistance in Gastrointestinal Stromal Tumors Harboring <i>KIT</i> AY502-3ins Mutation: An <i>In vitro</i> Mutagenesis Screen for Drug Resistance. Clinical Cancer Research, 2009, 15, 6862-6870.	3.2	86
311	Polypoid Lesions of the Gallbladder: Diagnosis and Followup. Journal of the American College of Surgeons, 2009, 208, 570-575.	0.2	109
312	Laparoscopic versus Open Liver Resection: A Matched-Pair Case Control Study. Journal of Gastrointestinal Surgery, 2009, 13, 2276-2283.	0.9	124
313	A Matched Case-Control Study of Preoperative Biliary Drainage in Patients with Pancreatic Adenocarcinoma: Routine Drainage Is Not Justified. Journal of Gastrointestinal Surgery, 2009, 13, 2163-2169.	0.9	108
314	Role of preoperative biliary drainage of liver remnant prior to extended liver resection for hilar cholangiocarcinoma. Hpb, 2009, 11, 445-451.	0.1	142
315	Analysis of the Extent of Resection for Adenocarcinoma of the Gallbladder. Annals of Surgical Oncology, 2009, 16, 806-816.	0.7	220
316	Synchronous Hepatic Metastases from Colon Cancer: Changing Treatment Strategies and Results of Surgical Intervention. Annals of Surgical Oncology, 2009, 16, 361-370.	0.7	39
317	Nanoneoadjuvant Therapy of Gastrointestinal Stromal Tumor (GIST). Annals of Surgical Oncology, 2009, 16, 799-800.	0.7	12
318	Liver Resection for Metastatic Colorectal Cancer in Patients with Concurrent Extrahepatic Disease: Results in 127 Patients Treated at a Single Center. Annals of Surgical Oncology, 2009, 16, 2138-2146.	0.7	145
319	T Cell Infiltrate Predicts Long-Term Survival Following Resection of Colorectal Cancer Liver Metastases. Annals of Surgical Oncology, 2009, 16, 2524-2530.	0.7	116
320	Human Liver Dendritic Cells Promote T Cell Hyporesponsiveness. Journal of Immunology, 2009, 182, 1901-1911.	0.4	186
321	Multidisciplinary Treatment of Gastrointestinal Stromal Tumors. Surgical Clinics of North America, 2009, 89, 217-233.	0.5	44
322	Development and validation of a prognostic nomogram for recurrence-free survival after complete surgical resection of localised primary gastrointestinal stromal tumour: a retrospective analysis. Lancet Oncology, The, 2009, 10, 1045-1052.	5.1	430
323	Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial. Lancet, The, 2009, 373, 1097-1104.	6.3	1,233
324	Management of Resectable Gastrointestinal Stromal Tumor. Hematology/Oncology Clinics of North America, 2009, 23, 79-96.	0.9	34

#	Article	IF	CITATIONS
325	Predicting the Risk of Perioperative Transfusion for Patients Undergoing Elective Hepatectomy. Annals of Surgery, 2009, 250, 914-921.	2.1	83
326	Operative Blood Loss Independently Predicts Recurrence and Survival After Resection of Hepatocellular Carcinoma. Annals of Surgery, 2009, 249, 617-623.	2.1	355
327	Dendritic cells are required for effective cross-presentation in the murine liver. Hepatology, 2008, 47, 1343-1351.	3.6	29
328	Tumor mitotic rate, size, and location independently predict recurrence after resection of primary gastrointestinal stromal tumor (GIST). Cancer, 2008, 112, 608-615.	2.0	437
329	Histologic grade is correlated with outcome after resection of hepatic neuroendocrine neoplasms. Cancer, 2008, 113, 126-134.	2.0	81
330	Novel V600E BRAF mutations in imatinibâ€naive and imatinibâ€resistant gastrointestinal stromal tumors. Genes Chromosomes and Cancer, 2008, 47, 853-859.	1.5	329
331	Prognostic Factors for Primary GIST: Prime Time for Personalized Therapy?. Annals of Surgical Oncology, 2008, 15, 4-6.	0.7	18
332	Perihepatic Lymph Node Micrometastases Impact Outcome after Partial Hepatectomy for Colorectal Metastases. Annals of Surgical Oncology, 2008, 15, 1130-1136.	0.7	34
333	Clinical Significance of Intraoperative Bile Duct Margin Assessment for Hilar Cholangiocarcinoma. Annals of Surgical Oncology, 2008, 15, 2104-2112.	0.7	111
334	Preoperative CA 19-9 and the Yield of Staging Laparoscopy in Patients with Radiographically Resectable Pancreatic Adenocarcinoma. Annals of Surgical Oncology, 2008, 15, 3512-3520.	0.7	168
335	Evidence-Guided Surgical Management of GIST: Beyond a Simple Case of Benign and Malignant. Annals of Surgical Oncology, 2008, 15, 1542-1543.	0.7	5
336	Extrahepatic cholangiocarcinoma: a comparison of patients with resected proximal and distal lesions. Hpb, 2008, 10, 341-346.	0.1	40
337	Vancomycin-resistant enterococci exploit antibiotic-induced innate immune deficits. Nature, 2008, 455, 804-807.	13.7	553
338	18F-fluorodeoxyglucose Positron Emission Tomography Influences Management Decisions in Patients with Biliary Cancer. Journal of the American College of Surgeons, 2008, 206, 57-65.	0.2	259
339	A Novel Prognostic Nomogram Is More Accurate than Conventional Staging Systems for Predicting Survival after Resection of Hepatocellular Carcinoma. Journal of the American College of Surgeons, 2008, 206, 281-291.	0.2	114
340	Preoperative Radiographic Assessment of Hepatic Steatosis with Histologic Correlation. Journal of the American College of Surgeons, 2008, 206, 480-488.	0.2	87
341	Human liver cells mediate innate immune responses to bacterial infection via IL-12 and IL-18. Journal of the American College of Surgeons, 2008, 207, S38.	0.2	0
342	Circulating HLA-DR+ natural killer cells have potent lytic ability and weak antigen-presenting cell function. Human Immunology, 2008, 69, 469-474.	1.2	25

#	Article	IF	CITATIONS
343	Transcatheter Arterial Embolization with Only Particles for the Treatment of Unresectable Hepatocellular Carcinoma. Journal of Vascular and Interventional Radiology, 2008, 19, 862-869.	0.2	153
344	CD11c identifies a subset of murine liver natural killer cells that responds to adenoviral hepatitis. Journal of Leukocyte Biology, 2008, 84, 1039-1046.	1.5	27
345	Toll-like receptor 9 inhibition reduces mortality in polymicrobial sepsis. Journal of Experimental Medicine, 2008, 205, 1277-1283.	4.2	120
346	Molecular Characterization of Pediatric Gastrointestinal Stromal Tumors. Clinical Cancer Research, 2008, 14, 3204-3215.	3.2	233
347	Histopathologic and Immunohistochemical Features of Tissue Adherent to Multitined Electrodes after RF Ablation of Liver Malignancies Can Help Predict Local Tumor Progression: Initial Results. Radiology, 2008, 249, 364-374.	3.6	59
348	Effect of Postoperative Morbidity on Long-term Survival After Hepatic Resection for Metastatic Colorectal Cancer. Annals of Surgery, 2008, 247, 994-1002.	2.1	201
349	Increased Use of Parenchymal-Sparing Surgery for Bilateral Liver Metastases From Colorectal Cancer Is Associated With Improved Mortality Without Change in Oncologic Outcome. Annals of Surgery, 2008, 247, 109-117.	2.1	215
350	Combined Portal Vein Embolization and Neoadjuvant Chemotherapy As a Treatment Strategy for Resectable Hepatic Colorectal Metastases. Annals of Surgery, 2008, 247, 451-455.	2.1	162
351	A Nomogram for Predicting Disease-specific Survival After Hepatic Resection for Metastatic Colorectal Cancer. Annals of Surgery, 2008, 247, 282-287.	2.1	154
352	A Prospective Randomized Trial of Acute Normovolemic Hemodilution Compared to Standard Intraoperative Management in Patients Undergoing Major Hepatic Resection. Annals of Surgery, 2008, 248, 360-369.	2.1	134
353	Intrahepatic Cholangiocarcinoma. Annals of Surgery, 2008, 248, 84-96.	2.1	729
354	NK Dendritic Cells Expanded in IL-15 Exhibit Antitumor Responses In Vivo. Journal of Immunology, 2007, 179, 4654-4660.	0.4	22
355	NK Dendritic Cells Are Innate Immune Responders to <i>Listeria monocytogenes</i> Infection. Journal of Immunology, 2007, 178, 4411-4416.	0.4	36
356	MyD88-mediated signals induce the bactericidal lectin RegIIIÎ <sup>3</sup> and protect mice against intestinal <i>Listeria monocytogenes</i> infection. Journal of Experimental Medicine, 2007, 204, 1891-1900.	4.2	342
357	Pathologic and Molecular Heterogeneity in Imatinib-Stable or Imatinib-Responsive Gastrointestinal Stromal Tumors. Clinical Cancer Research, 2007, 13, 170-181.	3.2	118
358	Novel xenograft model expressing human hepatocyte growth factor shows ligand-dependent growth of c-Met–expressing tumors. Molecular Cancer Therapeutics, 2007, 6, 1460-1466.	1.9	24
359	Sorafenib Inhibits the Imatinib-Resistant <i>KIT T670I</i> Gatekeeper Mutation in Gastrointestinal Stromal Tumor. Clinical Cancer Research, 2007, 13, 4874-4881.	3.2	144
360	Results of Tyrosine Kinase Inhibitor Therapy Followed by Surgical Resection for Metastatic Gastrointestinal Stromal Tumor. Annals of Surgery, 2007, 245, 347-352.	2.1	273

#	Article	IF	CITATIONS
361	The Impact of Margins on Outcome After Hepatic Resection for Colorectal Metastasis. Annals of Surgery, 2007, 246, 295-300.	2.1	207
362	A Host Lipase Detoxifies Bacterial Lipopolysaccharides in the Liver and Spleen. Journal of Biological Chemistry, 2007, 282, 13726-13735.	1.6	89
363	Outcome of Metastatic GIST in the Era before Tyrosine Kinase Inhibitors. Annals of Surgical Oncology, 2007, 14, 134-142.	0.7	104
364	Murine liver plasmacytoid dendritic cells become potent immunostimulatory cells after Flt-3 ligand expansion. Hepatology, 2007, 45, 445-454.	3.6	58
365	Adjuvant Chemotherapy Improves Survival after Resection of Hepatic Colorectal Metastases: Analysis of Data from Two Continents. Journal of the American College of Surgeons, 2007, 204, 753-761.	0.2	175
366	Extrahepatic Bile Duct Carcinoid Tumors: Malignant Biliary Obstruction with a Good Prognosis. Journal of the American College of Surgeons, 2007, 205, 357-361.	0.2	26
367	Outcomes after Resection of Synchronous or Metachronous Hepatic and Pulmonary Colorectal Metastases. Journal of the American College of Surgeons, 2007, 205, 231-238.	0.2	192
368	Outcome After Hepatectomy for Multiple (Four or More) Colorectal Metastases in the Era of Effective Chemotherapy. Annals of Surgical Oncology, 2007, 14, 1151-1160.	0.7	138
369	Lack of Evidence for Increased Operative Morbidity After Hepatectomy with Perioperative Use of Bevacizumab: A Matched Case-Control Study. Annals of Surgical Oncology, 2007, 14, 759-765.	0.7	161
370	Neoadjuvant Therapy for Gastrointestinal Stromal Tumor (GIST): Racing Against Resistance. Annals of Surgical Oncology, 2007, 14, 1247-1248.	0.7	35
371	Autologous Versus Allogeneic Transfusions: No Difference in Perioperative Outcome After Partial Hepatectomy. Journal of Gastrointestinal Surgery, 2007, 11, 1286-1293.	0.9	14
372	Prognostic Significance of Pathologic Nodal Status in Patients with Resected Pancreatic Cancer. Journal of Gastrointestinal Surgery, 2007, 11, 1549-1555.	0.9	176
373	Detection of Micrometastases in Peritoneal Washings of Pancreatic Cancer Patients by the Reverse Transcriptase Polymerase Chain Reaction. Journal of Gastrointestinal Surgery, 2007, 11, 1598-1606.	0.9	13
374	NCCN Task Force Report: Management of Patients with Gastrointestinal Stromal Tumor (GIST)—Update of the NCCN Clinical Practice Guidelines. Journal of the National Comprehensive Cancer Network: JNCCN, 2007, 5, S-1-S-29.	2.3	360
375	NCCN Task Force report: management of patients with gastrointestinal stromal tumor (GIST)update of the NCCN clinical practice guidelines. Journal of the National Comprehensive Cancer Network: JNCCN, 2007, 5 Suppl 2, S1-29; quiz S30.	2.3	201
376	Comparative Ultrastructural Analysis andKIT/PDGFRAGenotype in 125 Gastrointestinal Stromal Tumors. Ultrastructural Pathology, 2006, 30, 443-452.	0.4	21
377	In vivo overexpression of Flt3 ligand expands and activates murine spleen natural killer dendritic cells. FASEB Journal, 2006, 20, 982-984.	0.2	35
378	Combined Resection of Liver and Lung Metastases for Colorectal Cancer. Thoracic Surgery Clinics, 2006, 16, 145-155.	0.4	17

#	Article	IF	CITATIONS
379	Combined Surgical and Molecular Therapy. Annals of Surgery, 2006, 244, 176-184.	2.1	241
380	Perihepatic Lymph Node Assessment in Patients Undergoing Partial Hepatectomy for Malignancy. Annals of Surgery, 2006, 244, 260-264.	2.1	106
381	Profile of Plasma Angiogenic Factors Before and After Hepatectomy for Colorectal Cancer Liver Metastases. Annals of Surgical Oncology, 2006, 13, 353-362.	0.7	59
382	Treatment of Advanced Gastrointestinal Stromal Tumor: a Marriage of Targeted Therapy and Surgery?. Annals of Surgical Oncology, 2006, 14, 1-2.	0.7	9
383	Optimal Abdominal Incision for Partial Hepatectomy: Increased Late Complications with Mercedes-type Incisions Compared to Extended Right Subcostal Incisions. World Journal of Surgery, 2006, 30, 410-418.	0.8	56
384	The addition of extensive upper abdominal surgery to achieve optimal cytoreduction improves survival in patients with stages IIIC–IV epithelial ovarian cancer. Gynecologic Oncology, 2006, 103, 1083-1090.	0.6	305
385	Natural killer dendritic cells proliferate and secrete IFN-gamma during sepsis. Journal of the American College of Surgeons, 2006, 203, S33.	0.2	0
386	Interleukin-18 and the toll-like receptor 9 ligand CpG stimulate murine splenic natural killer dendritic cells (NKDC) to proliferate and secrete IFN-gamma. Journal of the American College of Surgeons, 2006, 203, S79-S80.	0.2	1
387	Treatment of metastatic sarcoma to the liver with bland embolization. Cancer, 2006, 107, 1617-1623.	2.0	64
388	Combined Stimulation with Interleukin-18 and CpG Induces Murine Natural Killer Dendritic Cells to Produce IFN-γ and Inhibit Tumor Growth. Cancer Research, 2006, 66, 10497-10504.	0.4	67
389	Biliary Obstruction Selectively Expands and Activates Liver Myeloid Dendritic Cells. Journal of Immunology, 2006, 176, 7189-7195.	0.4	31
390	Differential Cell Cycle–Regulatory Protein Expression in Biliary Tract Adenocarcinoma: Correlation With Anatomic Site, Pathologic Variables, and Clinical Outcome. Journal of Clinical Oncology, 2006, 24, 1152-1160.	0.8	80
391	Partial Hepatectomy for Metastases From Noncolorectal, Nonneuroendocrine Carcinoma. Annals of Surgery, 2005, 241, 269-276.	2.1	175
392	Gastrointestinal Stromal Tumors in Children and Young Adults. Journal of Pediatric Hematology/Oncology, 2005, 27, 179-187.	0.3	239
393	Papillary Phenotype Confers Improved Survival After Resection of Hilar Cholangiocarcinoma. Annals of Surgery, 2005, 241, 703-714.	2.1	172
394	Molecular mechanisms in hepatocellular carcinoma development. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2005, 19, 25-37.	1.0	95
395	Hepatic Resection for Other Metastases. Annals of Surgical Oncology, 2005, 12, 763-764.	0.7	1
396	Caudate hepatectomy for cancer: A single institution experience with 150 patients. Journal of the American College of Surgeons, 2005, 200, 345-352.	0.2	68

#	Article	IF	CITATIONS
397	Clinical and Pathologic Features of Proximal Biliary Strictures Masquerading as Hilar Cholangiocarcinoma. Journal of the American College of Surgeons, 2005, 201, 862-869.	0.2	119
398	Conventional liver CD4 T cells are functionally distinct and suppressed by environmental factors. Hepatology, 2005, 42, 293-300.	3.6	28
399	Natural Killer Dendritic Cells Have Both Antigen Presenting and Lytic Function and in Response to CpG Produce IFN-γ via Autocrine IL-12. Journal of Immunology, 2005, 174, 2612-2618.	0.4	131
400	Acquired Resistance to Imatinib in Gastrointestinal Stromal Tumor Occurs Through Secondary Gene Mutation. Clinical Cancer Research, 2005, 11, 4182-4190.	3.2	768
401	Surgical Therapy for Metastatic Disease to the Liver. Annual Review of Medicine, 2005, 56, 139-156.	5.0	119
402	Phase I Trial of Systemic Oxaliplatin Combination Chemotherapy With Hepatic Arterial Infusion in Patients With Unresectable Liver Metastases From Colorectal Cancer. Journal of Clinical Oncology, 2005, 23, 4888-4896.	0.8	201
403	Comparison of Survival Rates after Bland Arterial Embolization and Ablation Versus Surgical Resection for Treating Solitary Hepatocellular Carcinoma up to 7 cm. Journal of Vascular and Interventional Radiology, 2005, 16, 955-961.	0.2	86
404	Hepatic Follicular Dendritic Cell Sarcoma Without Epstein-Barr Virus Expression. Archives of Pathology and Laboratory Medicine, 2005, 129, 1480-1483.	1.2	26
405	Liver Sinusoidal Endothelial Cells Are Insufficient to Activate T Cells. Journal of Immunology, 2004, 173, 230-235.	0.4	110
406	Liver Dendritic Cells Are Less Immunogenic Than Spleen Dendritic Cells because of Differences in Subtype Composition. Journal of Immunology, 2004, 172, 1009-1017.	0.4	201
407	Increased and Long-Term Generation of Dendritic Cells with Reduced Function from IL-6-Deficient Bone Marrow. Journal of Immunology, 2004, 172, 7408-7416.	0.4	40
408	Improved optimal cytoreduction rates for stages IIIC and IV epithelial ovarian, fallopian tube, and primary peritoneal cancer: a change in surgical approach. Gynecologic Oncology, 2004, 94, 650-654.	0.6	286
409	Major hepatectomy with simultaneous pancreatectomy for advanced hepatobiliary cancer1 1No competing interests declared Journal of the American College of Surgeons, 2004, 198, 570-576.	0.2	58
410	Jaundice Predicts Advanced Disease and Early Mortality in Patients With Gallbladder Cancer. Annals of Surgical Oncology, 2004, 11, 310-315.	0.7	197
411	Natural killer cell depletion confounds the antitumor mechanism of endogenous IL-12 overexpression. International Journal of Cancer, 2004, 110, 395-402.	2.3	6
412	Gene Expression in Gastrointestinal Stromal Tumors Is Distinguished by KIT Genotype and Anatomic Site. Clinical Cancer Research, 2004, 10, 3282-3290.	3.2	194
413	Genomic Alterations in Gastrointestinal Stromal Tumors as Revealed by Conventional and Array-based Comparative Genomic Hybridization. Cancer Genomics and Proteomics, 2004, 1, 105-116.	1.0	0
414	GM-CSF expands dendritic cells and their progenitors in mouse liver. Hepatology, 2003, 37, 641-652.	3.6	36

#	Article	IF	CITATIONS
415	Optimization of dendritic cell maturation and gene transfer by recombinant adenovirus. Cancer Immunology, Immunotherapy, 2003, 52, 347-358.	2.0	26
416	The use of fresh frozen plasma after major hepatic resection for colorectal metastasis: is there a standard for transfusion?. Journal of the American College of Surgeons, 2003, 196, 402-409.	0.2	75
417	Simultaneous liver and colorectal resections are safe for synchronous colorectal liver metastasis. Journal of the American College of Surgeons, 2003, 197, 233-241.	0.2	377
418	Diagnosis, management, and outcomes of 115 patients with hepatic hemangioma. Journal of the American College of Surgeons, 2003, 197, 392-402.	0.2	195
419	Predictors and patterns of recurrence after resection of hepatocellular carcinoma. Journal of the American College of Surgeons, 2003, 197, 753-758.	0.2	260
420	Selective loss of c-Rel compromises dendritic cell activation of T lymphocytes. Cellular Immunology, 2003, 222, 105-115.	1.4	34
421	Targeted molecular therapy for cancer: The application of STI571 to gastrointestinal stromal tumor. Current Problems in Surgery, 2003, 40, 131-193.	0.6	4
422	Resection of recurrent ovarian or fallopian tube carcinoma involving the liverâ~†. Gynecologic Oncology, 2003, 91, 383-388.	0.6	51
423	Impact of steatosis on perioperative outcome following hepatic resection. Journal of Gastrointestinal Surgery, 2003, 7, 1034-1044.	0.9	387
424	Importance of Response to Neoadjuvant Chemotherapy in Patients Undergoing Resection of Synchronous Colorectal Liver Metastases. Journal of Gastrointestinal Surgery, 2003, 7, 109-117.	0.9	273
425	Volumetric Analysis Predicts Hepatic Dysfunction in Patients Undergoing Major Liver Resection. Journal of Gastrointestinal Surgery, 2003, 7, 325-330.	0.9	433
426	Overexpression of interleukinâ€12 enables dendritic cells to activate NK cells and confer systemic antitumor immunity. FASEB Journal, 2003, 17, 728-730.	0.2	41
427	Murine Flt3 Ligand Expands Distinct Dendritic Cells with Both Tolerogenic and Immunogenic Properties. Journal of Immunology, 2003, 170, 3554-3564.	0.4	61
428	Resection of Hepatocellular Carcinoma in Patients Otherwise Eligible for Transplantation. Annals of Surgery, 2003, 238, 315-323.	2.1	204
429	Breath-Hold Magnetic Resonance Cholangiopancreatography in the Evaluation of Malignant Pancreaticobiliary Obstruction. Journal of Computer Assisted Tomography, 2003, 27, 307-314.	0.5	24
430	Influence of Transfusions on Perioperative and Long-Term Outcome in Patients Following Hepatic Resection for Colorectal Metastases. Annals of Surgery, 2003, 237, 860-870.	2.1	493
431	Association of KIT exon 9 mutations with nongastric primary site and aggressive behavior: KIT mutation analysis and clinical correlates of 120 gastrointestinal stromal tumors. Clinical Cancer Research, 2003, 9, 3329-37.	3.2	280
432	Endogenous Granulocyte-Macrophage Colony-Stimulating Factor Overexpression In Vivo Results in the Long-Term Recruitment of a Distinct Dendritic Cell Population with Enhanced Immunostimulatory Function. Journal of Immunology, 2002, 169, 2875-2885.	0.4	63

#	Article	IF	CITATIONS
433	Second Liver Resections Are Safe and Effective Treatment for Recurrent Hepatic Metastases from Colorectal Cancer. Annals of Surgery, 2002, 235, 863-871.	2.1	284
434	Staging Laparoscopy in Patients With Extrahepatic Biliary Carcinoma. Annals of Surgery, 2002, 235, 392-399.	2.1	232
435	Surgery and Ablative Therapy for Hepatocellular Carcinoma. Journal of Clinical Gastroenterology, 2002, 35, S130-S137.	1.1	61
436	An audit of results of a no-drainage practice policy after hepatectomy. American Journal of Surgery, 2002, 184, 441-445.	0.9	53
437	Clinical management of gastrointestinal stromal tumors: Before and after STI-571. Human Pathology, 2002, 33, 466-477.	1.1	561
438	Combined hepatocellular and cholangiocarcinoma. Cancer, 2002, 94, 2040-2046.	2.0	300
439	The GIST of targeted cancer therapy: A tumor (Gastrointestinal stromal tumor), a mutated gene (c-kit), and a molecular inhibitor (STI571). Annals of Surgical Oncology, 2002, 9, 831-839.	0.7	132
440	Diabetes Is Associated With Increased Perioperative Mortality but Equivalent Long-Term Outcome After Hepatic Resection for Colorectal Cancer. Journal of Gastrointestinal Surgery, 2002, 6, 88-94.	0.9	115
441	Improvement in perioperative outcome after hepatic resection: analysis of 1,803 consecutive cases over the past decade. Annals of Surgery, 2002, 236, 397-406; discussion 406-7.	2.1	769
442	Adenovirus infection enhances dendritic cell immunostimulatory properties and induces natural killer and T-cell-mediated tumor protection. Cancer Research, 2002, 62, 5260-6.	0.4	89
443	The Role of Adjuvant Therapy After Liver Resection for Colorectal Cancer Metastase. Clinical Colorectal Cancer, 2001, 1, 154-166.	1.0	9
444	Cytokine Gene Transfer Enhances Herpes Oncolytic Therapy in Murine Squamous Cell Carcinoma. Human Gene Therapy, 2001, 12, 253-265.	1.4	132
445	Results of Hepatic Resection for Sarcoma Metastatic to Liver. Annals of Surgery, 2001, 234, 540-548.	2.1	222
446	Staging, Resectability, and Outcome in 225 Patients With Hilar Cholangiocarcinoma. Annals of Surgery, 2001, 234, 507-519.	2.1	1,153
447	Gastrointestinal Stromal Tumors and Leiomyosarcoma of the Abdomen and Retroperitoneum: A Clinical Comparison. Annals of Surgical Oncology, 2001, 8, 290-299.	0.7	108
448	A clinical scoring system predicts the yield of diagnostic laparoscopy in patients with potentially resectable hepatic colorectal metastases. Cancer, 2001, 91, 1121-1128.	2.0	146
449	What is the yield of intraoperative ultrasonography during partial hepatectomy for malignant disease?. Journal of the American College of Surgeons, 2001, 192, 577-583.	0.2	100
450	Intrahepatic Cholangiocarcinoma: resectability, recurrence pattern, and outcomes. Journal of the American College of Surgeons, 2001, 193, 384-391.	0.2	343

#	Article	IF	CITATIONS
451	Peritoneal washings are not predictive of occult peritoneal disease in patients with hilar cholangiocarcinoma1 1No competing interests declared Journal of the American College of Surgeons, 2001, 193, 620-625.	0.2	17
452	A clinical scoring system predicts the yield of diagnostic laparoscopy in patients with potentially resectable hepatic colorectal metastases. , 2001, 91, 1121.		1
453	Gastrointestinal Stromal Tumors and Leiomyosarcoma of the Abdomen and Retroperitoneum: A Clinical Comparison. , 2001, 8, 290.		64
454	Two Hundred Gastrointestinal Stromal Tumors. Annals of Surgery, 2000, 231, 51.	2.1	2,236
455	Recent advances in hepatic resection. Journal of Surgical Oncology, 2000, 19, 200-207.	1.4	72
456	Genes and viruses in hepatobiliary neoplasia. Journal of Surgical Oncology, 2000, 19, 84-93.	1.4	30
457	Survival After Resection of Multiple Hepatic Colorectal Metastases. Annals of Surgical Oncology, 2000, 7, 643-650.	0.7	170
458	Surgical treatment of malignant liver tumours. Bailliere's Best Practice and Research in Clinical Gastroenterology, 1999, 13, 557-574.	1.0	24
459	Cellular Immunity Delimits Adenoviral Gene Therapy Strategies for the Treatment of Neoplastic Diseases. Annals of Surgical Oncology, 1999, 6, 88-94.	0.7	25
460	Effect of Adenoviral Early Genes and the Host Immune System on In Vivo Pancreatic Gene Transfer in the Mouse. Pancreas, 1997, 15, 236-245.	0.5	19
461	Adenoviral-mediated gene transfer to murine small intestine is more efficient in neonates than adults. Journal of Pediatric Surgery, 1997, 32, 373-377.	0.8	18
462	IMMUNOLOGIC BARRIERS TO HEPATIC ADENOVIRAL GENE THERAPY FOR TRANSPLANTATION. Transplantation, 1997, 63, 315-319.	0.5	41
463	Adenovirus-Mediated In Vivo Gene Transfer and Expression in Normal Rat Pancreas. Pancreas, 1996, 12, 401-410.	0.5	49
464	AN IMPROVED TECHNIQUE OF THYMECTOMY IN THE ADULT MOUSE. Transplantation, 1995, 59, 787-789.	0.5	4
465	Gene Transfer to the Thymus A Means of Abrogating the Immune Response to Recombinant Adenovirus. Annals of Surgery, 1995, 222, 229-242.	2.1	70
466	Divergent mechanisms of insulin-like growth factor I and II on rat hepatocyte proliferation. Regulatory Peptides, 1995, 58, 55-62.	1.9	6
467	Sarcoma and Gastrointestinal Stromal Tumors. , 0, , 227-258.		0